Kubra Kızıltac
Research Subjects
Kubra Kızıltac has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Emek Kocatürk
Institute of Allergology Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
3 shared publications - Ralfi Singer
Department of Dermatology Prof Dr Cemil Tascioglu City Hospital Istanbul Turkey
3 shared publications - Ece Nur Degirmentepe
Dermatology Clinic Private Practice Sakarya Turkey
2 shared publications - Bachar Memet
Department of Dermatology and Venereology, Okmeydanı Training and Research Hospital, Istanbul, Turkey
1 shared publication - Cihat Örken
Clinic of Neurology, Prof. Dr. Cemil Taşçıoğlu City Hospital, University of Health Sciences Turkey, Istanbul, Turkey
1 shared publication - Mehmet Sitki Copur
Mary Lanning Healthcare, Morrison Cancer Center, Hastings, NE; University of Nebraska Medical Center, Adjunct Faculty, Omaha, NE
1 shared publication
Latest Publications
- Open Access
- 22 November 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (3) , 513-520
A comparative analysis of chronic inducible urticaria in 423 patients: Clinical and laboratory features and comorbid conditions
Background: Chronic inducible urticaria (CIndU) is a subtype of chronic urticaria (CU) which require specific physical or non‐physical triggers to occur. They may be isolated or may coexist with chronic spontaneous urticaria (CSU). Despite their frequent appearance in dermatology clinics, there is scarce information on the distinguishing features among the most common subtypes of CIndU as well as isolated CIndU versus CSU plus CIndU.Objectives: To compare clinical and laboratory characteristics, and comorbid conditions among the most common CIndU types and isolated CIndU versus CSU plus CIndU.Methods: We retrospectively analysed CIndU patients and compared patients' demographic, clinical and laboratory characteristics across isolated CIndU, CSU plus CIndU, symptomatic dermographism (SD), cold urticaria (ColdU) and cholinergic urticaria (ChoU).Results: A total of 423 patients (~70% isolated CIndU, ~30% CSU plus CIndU, ~5% mixed CIndU subtypes) were included in the study. The most frequent CIndU subtypes were SD (68.6%; 290/423), ColdU (11.4%; 48/423) and ChoU (10.9%; 46/423). Isolated CIndU patients were younger than CSU plus CIndU (33.74 ± 12.72 vs. 37.06 ± 11.84, p = 0.010). Angioedema, emergency referrals, need for systemic steroids, comorbid systemic disorders were more frequent and baseline urticaria control test scores were lower in CSU plus CIndU patients (vs. CIndU, p < 0.001, p = 0.008, p < 0.001, p = 0.031, p = 0.036, respectively). Among CIndU subtypes, ChoU patients were younger (24.9 ± 12.2 vs. 34.47 ± 12.12 vs. 31.38 ± 14.95; p < 0.001) and had male predominance (p < 0.001) while SD patients had no angioedema (p < 0.001) and had higher frequency of increased total IgE levels (p = 0.006).Conclusions: Isolated CIndU and CSU plus CIndU seems to be different endotypes of CU where CSU plus CIndU presents a more severe and refractory course. There are distinctive features of each CIndU subtype. These suggest involvement of different pathomechanistic pathways in these subtypes that need to be clarified in future studies.
- 22 November 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (3) , 513-520
Open AccessA comparative analysis of chronic inducible urticaria in 423 patients: Clinical and laboratory features and comorbid conditions
Background: Chronic inducible urticaria (CIndU) is a subtype of chronic urticaria (CU) which require specific physical or non‐physical triggers to occur. They may be isolated or may coexist with chronic spontaneous urticaria (CSU). Despite their frequent appearance in dermatology clinics, there is scarce information on the distinguishing features among the most common subtypes of CIndU as well as isolated CIndU versus CSU plus CIndU.Objectives: To compare clinical and laboratory characteristics, and comorbid conditions among the most common CIndU types and isolated CIndU versus CSU plus CIndU.Methods: We retrospectively analysed CIndU patients and compared patients' demographic, clinical and laboratory characteristics across isolated CIndU, CSU plus CIndU, symptomatic dermographism (SD), cold urticaria (ColdU) and cholinergic urticaria (ChoU).Results: A total of 423 patients (~70% isolated CIndU, ~30% CSU plus CIndU, ~5% mixed CIndU subtypes) were included in the study. The most frequent CIndU subtypes were SD (68.6%; 290/423), ColdU (11.4%; 48/423) and ChoU (10.9%; 46/423). Isolated CIndU patients were younger than CSU plus CIndU (33.74 ± 12.72 vs. 37.06 ± 11.84, p = 0.010). Angioedema, emergency referrals, need for systemic steroids, comorbid systemic disorders were more frequent and baseline urticaria control test scores were lower in CSU plus CIndU patients (vs. CIndU, p < 0.001, p = 0.008, p < 0.001, p = 0.031, p = 0.036, respectively). Among CIndU subtypes, ChoU patients were younger (24.9 ± 12.2 vs. 34.47 ± 12.12 vs. 31.38 ± 14.95; p < 0.001) and had male predominance (p < 0.001) while SD patients had no angioedema (p < 0.001) and had higher frequency of increased total IgE levels (p = 0.006).Conclusions: Isolated CIndU and CSU plus CIndU seems to be different endotypes of CU where CSU plus CIndU presents a more severe and refractory course. There are distinctive features of each CIndU subtype. These suggest involvement of different pathomechanistic pathways in these subtypes that need to be clarified in future studies.
- Open Access
- 4 April 2019
- Published by Galenos Yayinevi in TURKDERM
- Vol. 53 (1) , 24-27
Polyneuropathy developing after infliximab therapy in a patient with recalcitrant pyoderma gangrenosum
- 4 April 2019
- Published by Galenos Yayinevi in TURKDERM
- Vol. 53 (1) , 24-27
Open AccessPolyneuropathy developing after infliximab therapy in a patient with recalcitrant pyoderma gangrenosum
- Open Access
- 1 January 2019
- Published by XMLink in Annals of Dermatology
- Vol. 31 (3) , 335-338
Omalizumab as a Succesfull Therapy in Normocomplementemic Urticarial Vasculitis: A Series of Four Patients and Review of the Literature
Degirmentepe EN, et al. Ann Dermatol. 2019 Jun;31(3):335-338. https://doi.org/10.5021/ad.2019.31.3.335
- 1 January 2019
- Published by XMLink in Annals of Dermatology
- Vol. 31 (3) , 335-338
Open AccessOmalizumab as a Succesfull Therapy in Normocomplementemic Urticarial Vasculitis: A Series of Four Patients and Review of the Literature
Degirmentepe EN, et al. Ann Dermatol. 2019 Jun;31(3):335-338. https://doi.org/10.5021/ad.2019.31.3.335